Qingdao Xingsai Biotechnology
A developer of single-cell analysis instruments and supporting reagents and consumables.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
Related Content
Established in 2014 and headquartered in Qingdao, China, Qingdao Xingsai Biotechnology Co., Ltd. operates within the biotechnology and medical device sectors, specializing in single-cell analysis. The company's revenue model is centered on the development and sale of scientific instruments, associated software, and reagent consumables. Their offerings provide solutions for metabolic phenome-based single-cell imaging, sorting, sequencing, and culture.
The company's product portfolio is segmented into instruments, kits & chips, and software. Key instruments include the FlowRACS, a high-throughput flow Raman sorter; the CAST-R for clinical antimicrobial susceptibility testing; and the RACS-Seq for Raman-activated cell sorting and sequencing. Their software suite, comprising RamEX, RamDB, and RamLIS, supports the hardware. These products serve a diverse client base across precision medicine, human and environmental micro-ecology, and bioresource mining.
A significant figure in the company is co-founder Xu Jian, who also serves as the director of the Bioenergy Research Office and the Single Cell Center of the Qingdao Institute of Energy, Chinese Academy of Sciences. The company has secured strategic funding, including a round in April 2024, with investors such as Neovision Capital, Nanjing Gaoke, and Hengxu Capital backing its growth.
Keywords: single-cell analysis, biotechnology, medical devices, metabolic phenome, precision medicine, Raman spectroscopy, cell sorting, sequencing instruments, micro-ecology, bioresource mining